Abstract:Introduction Gastric cancer (GC) is the fourth most common cancer and the third-leading cause of cancer-related deaths worldwide. Despite certain advances in chemotherapy regimens and targeted therapies, the 5 year survival of patients with advanced GC is disappointing. The positive results of the apatinib phase III trial have cast new light on treatment for patients with advanced gastric cancer (GC) refractory to two or more lines of prior systemic chemotherapies. However, a dose reduction or treatment interruption is required to prevent apatinib toxicity such as hand-foot skin reaction (HFSR), proteinuria, and hypertension. In addition, suitable biomarkers are not accessible for identifying the patients who are most likely to benefit from apatinib. Therefore, predictive biomarkers are urgently needed to reduce toxicity and identify patients that will benefit from apatinib treatment. Material and methods Clonogenic assay, cytotoxicity assay, apoptosis assay, qRT-PCR, western blot were conducted in GC cells to evaluate the effectiveness of apatinib in vitro. Confocal microscopy assay was peformed to examine apatinib-induced autophagic flux in GC cells. Transmission electron microscopy assay was conducted to show the formation of autophagic vesicles. Xenograft models in mice were conducted and six tumour tissues were sent for miRNA-seq and circRNA-seq. Sanger sequencing was applied to determine the full length of the amplification products. Results and discussions In this study, we found that apatinib inhibited the growth of GC cells and xenograft tumours. Apatinib promoted autophagy activation via upregulation of ATG7 expression, and autophagy inhibition enhanced apatinib-induced apoptosis. With miRNA-seq and circRNA-seq analyses of GC xenograft models, we demonstrated that circRNA004582 functioned as an endogenous sponge for miR-3657 to inhibit its activity and further upregulate ATG7 expression. Silencing of circRNA004582 inhibited apatinib-induced autophagy, which was rescued by miR-3657. Moreover, knockdown of circRNA004582 promoted apatinib-induced apoptosis in GC cells. These findings provided the first evidence that the circRNA004582-miR-3657-ATG7 axis mediates a regulatory pathway critical for the regulation of autophagy and apatinib sensitivity in GC cells and xenografts. Conclusion In conclusion, specific blockage of circRNA004582 may be a potential therapeutic target for autophagy inhibition in the context of apatinib treatment in human GC. Prospective clinical studies are warranted to examine these biomarkers.

Ganoderic acid A suppresses autophagy by regulating the circFLNA/miR-486-3p/CYP1A1/XRCC1 axis to strengthen the sensitivity of lung cancer cells to cisplatin

Ganoderic Acid DM Induces Autophagic Apoptosis in Non-Small Cell Lung Cancer Cells by Inhibiting the PI3K/Akt/mTOR Activity.

Effects of Lncrna ANRIL-knockdown on the Proliferation, Apoptosis and Cell Cycle of Gastric Cancer Cells.

DDP Induced Cytotoxicity through miR-215-5p/COL5A1/FSTL1 Axis to Regulate Autophagy in Lung Adenocarcinoma Cells

circPGAM1 enhances autophagy signaling during laryngocarcinoma drug resistance by regulating miR-376a

PO-071 Silencing of Circrna004582 Sensitises Gastric Cancer Cells to APATINIB Via Modulating Autophagy by Targeting Mir-3657 and ATG7

Andrographolide Enhances Cisplatin-Mediated Anticancer Effects in Lung Cancer Cells Through Blockade of Autophagy.

Ailanthone Increases Cisplatin-induced Apoptosis and Autophagy in Cisplatin Resistance Non-small Cell Lung Cancer Cells through the PI3K/AKT/mTOR Pathway

Impaired autophagic degradation of lncRNA ARHGAP5-AS1 promotes chemoresistance in gastric cancer

Proteomics reveals a therapeutic vulnerability via the combined blockade of APE1 and autophagy in lung cancer A549 cells

Inhibition of Autophagy by Andrographolide Resensitizes Cisplatin-Resistant Non-Small Cell Lung Carcinoma Cells Via Activation of the Akt/mTOR Pathway.

All-trans retinoic acid-mediated miR-30a up-regulation suppresses autophagy and sensitizes gastric cancer cells to cisplatin

Circular CPM promotes chemoresistance of gastric cancer via activating PRKAA2‐mediated autophagy

Silencing of Circracgap1 Sensitizes Gastric Cancer Cells to Apatinib Via Modulating Autophagy by Targeting Mir-3657 and ATG7

Circular RNA circ_ASAP2 regulates drug sensitivity and functional behaviors of cisplatin-resistant gastric cancer cells by the miR-330-3p/NT5E axis

Glycyrrhetinic Acid Triggers a Protective Autophagy by Activation of Extracellular Regulated Protein Kinases in Hepatocellular Carcinoma Cells

Gambogic Acid Improves Cisplatin Resistance of Bladder Cancer Cells through the Epithelial-Mesenchymal Transition Pathway Mediated by the miR-205-5p/ZEB1 Axis

Influence of autophagy on radiosensitivity of lung adenocarcinoma cells

Antrodin C, an NADPH Dependent Metabolism, Encourages Crosstalk between Autophagy and Apoptosis in Lung Carcinoma Cells by Use of an AMPK Inhibition-Independent Blockade of the Akt/mTOR Pathway

MicroRNA‐1 overexpression increases chemosensitivity of non‐small cell lung cancer cells by inhibiting autophagy related 3‐mediated autophagy

Gambogic acid exhibits promising anticancer activity by inhibiting the pentose phosphate pathway in lung cancer mouse model